Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,178 across all filing types
Latest filing 2024-04-15 AGM Information
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Proceedings of the 41st Annual General Meeting.
AGM Information Classification · 95% confidence The document is a communication addressed to stock exchanges regarding the proceedings of the 41st Annual General Meeting (AGM) held on August 3, 2023. It details the resolutions voted on by members, including adoption of audited financial statements, dividend declaration, director re-appointments, and remuneration ratification. The document is a summary of the AGM proceedings and voting outcomes, not the full AGM presentation materials or the full annual report. It is a formal announcement of the AGM proceedings as required by regulatory disclosure norms. Therefore, it fits the category of AGM Information (AGM-R). The document length is 3292 characters, which is consistent with a concise AGM proceedings announcement rather than a full report or transcript.
2024-04-15 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the stop transfer request from an investor. The document is addressed to stock exchanges and signed by the company secretary. It is a regulatory compliance filing related to share certificate handling and does not contain financial data, management discussion, or report content. The document length is short (2890 characters) and it is a formal certificate rather than a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS) as a compliance certificate filing.
2024-04-15 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the stop transfer request related to those shares. The document is addressed to stock exchanges and signed by the company secretary. It is a regulatory compliance filing related to share certificate handling and does not contain financial data, management discussion, or report content. It is not an annual report, earnings release, or any financial report. It is also not a voting result, capital update, or director dealing. The document is a regulatory filing notifying the stock exchanges about compliance with a specific regulation. Given the content and nature, the appropriate classification is Regulatory Filings (RNS). The document length is short and focused on compliance, fitting the RNS category with high confidence.
2024-04-15 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the stop transfer request related to those shares. The document is addressed to stock exchanges and signed by the company secretary. It is a regulatory compliance filing related to share certificate handling and does not contain financial data, management discussion, or report content. It is not an announcement of a report publication but a regulatory compliance certificate. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-04-12 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the stop transfer request related to those shares. The document is addressed to stock exchanges and signed by the company secretary. It is a regulatory compliance filing related to share certificate handling and does not contain financial data, management discussion, or report content. The document length is short (2892 characters) and it is a formal certificate rather than a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-04-12 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful completion of a U.S. FDA GMP inspection of Lupin's manufacturing facility with no observations. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material event disclosures. The document does not contain financial statements, detailed financial analysis, or management discussion of financial results. It is a regulatory disclosure about an operational event (inspection completion) rather than a financial report or earnings release. The document length is 4253 characters, which is relatively short and consistent with a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.